Recombinant multi-species BCL11A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCL11A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a C2H2 type zinc-finger protein by its similarity to the mouse Bcl11a/Evi9 protein. The corresponding mouse gene is a common site of retroviral integration in myeloid leukemia, and may function as a leukemia disease gene, in part, through its interaction with BCL6. During hematopoietic cell differentiation, this gene is down-regulated. It is possibly involved in lymphoma pathogenesis since translocations associated with B-cell malignancies also deregulates its expression. Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
The Alternative Names of target: BCL11A,B-cell lymphoma/leukemia 11A,BCL-11A,B-cell CLL/lymphoma 11A, COUP-TF-interacting protein 1, Ecotropic viral integration site 9 protein homolog (EVI-9), Zinc finger protein 856,EVI9,CTIP1,DILOS,ZNF856,HBFQTL5,SMARCM1

Target products collectionGo to BCL11A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T26470-Ab-1/ GM-Tg-hg-T26470-Ab-2 Human BCL11A protein Human
GM-Tg-rg-T26470-Ab-1/ GM-Tg-rg-T26470-Ab-2 Rat BCL11A protein Rat
GM-Tg-mg-T26470-Ab-1/ GM-Tg-mg-T26470-Ab-2 Mouse BCL11A protein Mouse
GM-Tg-cynog-T26470-Ab-1/ GM-Tg-cynog-T26470-Ab-2 Cynomolgus/Rhesus macaque BCL11A monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-T26470-Ab-1/ GM-Tg-felg-T26470-Ab-2 Feline BCL11A protein Feline
GM-Tg-cang-T26470-Ab-1/ GM-Tg-cang-T26470-Ab-2 Canine BCL11A protein Canine
GM-Tg-bovg-T26470-Ab-1/ GM-Tg-bovg-T26470-Ab-2 Bovine BCL11A protein Bovine
GM-Tg-equg-T26470-Ab-1/ GM-Tg-equg-T26470-Ab-2 Equine BCL11A protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T26470-Ab-1/ GM-Tg-hg-T26470-Ab-2; GM-Tg-rg-T26470-Ab-1/ GM-Tg-rg-T26470-Ab-2;
GM-Tg-mg-T26470-Ab-1/ GM-Tg-mg-T26470-Ab-2; GM-Tg-cynog-T26470-Ab-1/ GM-Tg-cynog-T26470-Ab-2;
GM-Tg-felg-T26470-Ab-1/ GM-Tg-felg-T26470-Ab-2; GM-Tg-cang-T26470-Ab-1/ GM-Tg-cang-T26470-Ab-2;
GM-Tg-bovg-T26470-Ab-1/ GM-Tg-bovg-T26470-Ab-2; GM-Tg-equg-T26470-Ab-1/ GM-Tg-equg-T26470-Ab-2
Products Name BCL11A protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name BCL11A
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCL11A protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.